Bharat Biotech Vaccine
Fair Pharma Scorecard
Toetst farmaceutische bedrijven op mensenrechten.
Menu
Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.
The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.
The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.
Moderna has a five-pillar strategy to ensure that low-income countries get access to its vaccine, including: not enforcing patents, supporting the Covax facility, facilitating donations by countries that bought more doses than they need, building an mRNA facility in Africa, and delivering between 2 to 3 billion doses to low-income countries in 2022.
Moderna has a human rights policy which does not mention compliance with UN Guiding Principles on Business and Human Rights.
The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.
Moderna has not shown evidence of supporting a responsible licensing mechanism such as C-TAP or the MPP.
In October 2020, Moderna vowed not to enforce its patent rights during the pandemic and that it would be willing to license them to others after the pandemic.
On 08 February 2022, Moderna updated this pledge, stating that it will “never enforce its patents for COVID-19 vaccines against manufacturers in or for the 92 low- and middle-income countries in the Gavi COVAX Advance Market Commitment (AMC), provided that the manufactured vaccines are solely for use in the AMC 92 countries.” This is a narrower version of Moderna’s previous pledge,
Moderna has donated 650 000 000 doses through COVAX.
Moderna has established multiple fill-and-finish and distribution sites: Cipla (India), Rovi Pharma (Nigeria), Thermo-fisher, Samsung Biologics.
The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.
[Only applies to therapeutics]
Moderna does not commit to full technology transfer to other manufacturers.
Moderna states that it will make profit from the vaccine. There are different prices for the vaccine but those paid by middle-income countries and low-income countries are sometimes more than what is paid by high-income countries (Botswana, eg, payed 28,88 US dollars and the EU paid 25,50). The different prices cannot therefore be considered as part of a differential pricing policy based on ability to pay.
Moderna has sold only 31.5% of its doses to low- and middle-income countries.
